These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 36264481)
1. Identification of Selective PPAR-γ Modulators by Combining Pharmacophore Modeling, Molecular Docking, and Adipogenesis Assay. Li Y; Ks N; Byran G; Krishnamurthy PT Appl Biochem Biotechnol; 2023 Feb; 195(2):1014-1041. PubMed ID: 36264481 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists. Najmi A; Alam MS; Thangavel N; Taha MME; Meraya AM; Albratty M; Alhazmi HA; Ahsan W; Haque A; Azam F Sci Rep; 2023 Nov; 13(1):19869. PubMed ID: 37963936 [TBL] [Abstract][Full Text] [Related]
3. Oxadiazolyl thiazolidinedione as a non-adipogenic PPAR-γ partial agonist and its effect on glucose homeostasis in type 2 diabetes. Thangavel N; Bratty MA; Javed SA; Ahsan W; Hazmi HA J Biol Regul Homeost Agents; 2019; 33(3):707-719. PubMed ID: 31204468 [TBL] [Abstract][Full Text] [Related]
4. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo. Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952 [TBL] [Abstract][Full Text] [Related]
13. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties. Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587 [TBL] [Abstract][Full Text] [Related]
14. Rational design and synthesis of some PPAR-γ agonists: Substituted benzylideneamino-benzylidene-thiazolidine-2,4-diones. Chhajed SS; Chaskar S; Kshirsagar SK; Haldar GM; Kar Mahapatra D Comput Biol Chem; 2017 Apr; 67():260-265. PubMed ID: 28193552 [TBL] [Abstract][Full Text] [Related]
15. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Higgins LS; Depaoli AM Am J Clin Nutr; 2010 Jan; 91(1):267S-272S. PubMed ID: 19906796 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators. Naim MJ; Alam O; Alam MJ; Shaquiquzzaman M; Alam MM; Naidu VGM Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700223. PubMed ID: 29400412 [TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists. Nazreen S; Alam MS; Hamid H; Shahar Yar M; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai K Arch Pharm (Weinheim); 2015 Jun; 348(6):421-32. PubMed ID: 25900064 [TBL] [Abstract][Full Text] [Related]
18. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention. Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887 [TBL] [Abstract][Full Text] [Related]
19. Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist. Agrawal R; Jain P; Dikshit SN Mini Rev Med Chem; 2012 Feb; 12(2):87-97. PubMed ID: 22372600 [TBL] [Abstract][Full Text] [Related]
20. Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. Doshi LS; Brahma MK; Bahirat UA; Dixit AV; Nemmani KV Expert Opin Investig Drugs; 2010 Apr; 19(4):489-512. PubMed ID: 20367191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]